Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Wei Jing, Liu"'
Autor:
Zheng-Jie He, Ke He, Song-Wang Cai, Rui Zhang, Zhong-Bao Shao, Sheng-Te Wang, Xiao-Peng Li, Yan-Chi Li, Wei-Jing Liu, You-Qing Zhu, Shi-Jie Zeng, Yu-Bin Su, Zhi Shi
Publikováno v:
Cell Death and Disease, Vol 15, Iss 7, Pp 1-13 (2024)
Abstract Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, and the expression and function of an uncharacterized protein RNF214 in HCC are still unknown. Phase separation has recently been observed to participate in the progr
Externí odkaz:
https://doaj.org/article/d20d162390344fbb810c2f4c0c803fb5
Autor:
Yun Wu, Ying Wang, Weijun Huang, Xi Guo, Baoluo Hou, Jingyi Tang, Yuqi Wu, Huijuan Zheng, Yanling Pan, Wei Jing Liu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionWe investigated the efficacy and safety of oral sodium bicarbonate in kidney-transplant recipients and non-transplant patients with chronic kidney disease (CKD), which are currently unclear.MethodsPubMed, Cochrane Library, Embase, and Web
Externí odkaz:
https://doaj.org/article/48e3288f6f994fab9874075687c42283
Autor:
Borui Yu, Mengqi Zhou, Zhaocheng Dong, Huijuan Zheng, Yuxue Zhao, Jingwei Zhou, Chao Zhang, Fudong Wei, Guoyong Yu, Wei Jing Liu, Hongfang Liu, Yaoxian Wang
Publikováno v:
Pharmaceutical Biology, Vol 61, Iss 1, Pp 1222-1233 (2023)
AbstractContext Diabetic nephropathy (DN) is the main cause of end-stage renal disease. Modified Shen-Yan-Fang-Shuai formula (M-SYFSF) has excellent clinical efficacy in treating diabetic kidney disease. However, the potential mechanism of M-SYFSF re
Externí odkaz:
https://doaj.org/article/3407f4e844cd425abc154a78f57932bd
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Diabetic kidney disease (DKD), a significant complication associated with diabetes mellitus, presents limited treatment options. The progression of DKD is marked by substantial lipid disturbances, including alterations in triglycerides, cholesterol,
Externí odkaz:
https://doaj.org/article/6c309a29ec5c4a12971eb1a9088f17d5
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/b09c37fd51b9409dae53bfc9c82befaf
Publikováno v:
Renal Failure, Vol 44, Iss 1, Pp 806-814 (2022)
Background/Objective Diabetes mellitus is a common “non-gout” disease with high incidence. Several studies have shown that serum uric acid level in patients with diabetes is higher than that in healthy individuals, and is accompanied by severe al
Externí odkaz:
https://doaj.org/article/92752303339b4365bfa693f876a3ce94
Autor:
Sinan Ai, Yake Li, JiaYin Tao, Huijuan Zheng, Lei Tian, Yaoxian Wang, Zhen Wang, Wei Jing Liu
Publikováno v:
Frontiers in Physiology, Vol 14 (2023)
Background: The gut-kidney axis refers to the interaction between the gastrointestinal tract and the kidneys, and its disorders have become increasingly important in the development of kidney diseases. The aim of this study is to identify current res
Externí odkaz:
https://doaj.org/article/ae768383457c4ba1a3a10ac6203ec80a
Autor:
Yi Zhen Han, Hui Juan Zheng, Bo Xuan Du, Yi Zhang, Xing Yu Zhu, Jing Li, Yao Xian Wang, Wei Jing Liu
Publikováno v:
Journal of Diabetes Research, Vol 2023 (2023)
Diabetic kidney disease (DKD) is a prevailing complication arising from diabetes mellitus. Unfortunately, there are no trustworthy and efficacious treatment modalities currently available. In recent times, compelling evidence has emerged regarding th
Externí odkaz:
https://doaj.org/article/822766b333dc47e5911828f7bdb980f0
Publikováno v:
Journal of Diabetes Research, Vol 2023 (2023)
Background. Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD), and there is growing evidence to support the role of immunity in the progression of DN to ESRD. Chemokines and chemokine receptors (CCRs) can recruit immune cel
Externí odkaz:
https://doaj.org/article/6da34b1f806c442999b492b2ef6be691
Autor:
Cheng Yuan Xue, Meng Qi Zhou, Qi Yan Zheng, Jin Hui Zhang, Wei Ting Cheng, Xue Hui Bai, Fen Zhou, Ai Ming Wu, Bo Nie, Wei Jing Liu, Li Xia Lou
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Rosiglitazone (Avandia) and pioglitazone (Actos) belong to the class of thiazolidinediones (TZDs) drugs that act by increasing insulin sensitivity and are widely used for treating diabetic patients with insulin resistance. TZDs exhibit anti-inflammat
Externí odkaz:
https://doaj.org/article/857b5ca70a93497e928d1ca8525aff20